Compare DSC & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSC | VCRE |
|---|---|---|
| Founded | N/A | N/A |
| Country | China | Sweden |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.5M | 316.4M |
| IPO Year | 2023 | 2026 |
| Metric | DSC | VCRE |
|---|---|---|
| Price | $6.57 | $9.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 41.9K | 15.8K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.52 | $9.64 |
| 52 Week High | $9.60 | $13.15 |
| Indicator | DSC | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | N/A |
| Support Level | $4.69 | N/A |
| Resistance Level | $6.70 | N/A |
| Average True Range (ATR) | 0.69 | 0.00 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 25.74 | 0.00 |
DSC Holdings Ltd is an AI application infrastructure for China's used car industry. According to CIC, the Company has held over 90% market share in operating systems for China's used car dealers, giving it nationwide dealer connections and massive, granular, proprietary, real-time industry data. Building on this digital foundation, the group further supports used car dealers with essential transaction services across their workflows. Its Services engage and benefit thousands of dealer collaborators, such as inspectors, transporters, and other internet platforms, creating an ecosystem with used car dealers at its center.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.